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Abstract 
Thanks to striking progress in both the understanding of anti-tumor immune response and the characterization of 
several tumor associated antigens (TAA), a more rational design and more sophisticated strategies for anti-tumor 
vaccination have been possible. However, the effectiveness of cancer vaccines in clinical trial is still partial, indicating 
that additional studies are needed to optimize their design and their pre-clinical testing. Indeed, anti-tumor vaccina-
tion success relies on the choice of the best TAA to be targeted and on the translational power of the pre-clinical 
model used to assess its efficacy. The chondroitin sulfate proteoglycan-4 (CSPG4) is a cell surface proteoglycan 
overexpressed in a huge range of human and canine neoplastic lesions by tumor cells, tumor microenvironment and 
cancer initiating cells. CSPG4 plays a central role in the oncogenic pathways required for malignant progression and 
metastatization. Thanks to these features and to its poor expression in adult healthy tissues, CSPG4 represents an ideal 
oncoantigen and thus an attractive target for anti-tumor immunotherapy. In this review we explore the potential of 
CSPG4 immune-targeting. Moreover, since it has been clearly demonstrated that spontaneous canine tumors mimic 
the progression of human malignancies better than any other pre-clinical model available so far, we reported also our 
results indicating that CSPG4 DNA vaccination is safe and effective in significantly increasing the survival of canine 
melanoma patients. Therefore, anti-CSPG4 vaccination strategy could have a substantial impact for the treatment of 
the wider population of spontaneous CSPG4-positive tumor affected dogs with a priceless translational value and a 
revolutionary implication for human oncological patients.
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Background
It is when oncology meets immunology that cancer 
immunotherapy begins. Strengthen the patient’s own 
immune response against cancer cells represents one of 
the most challenging and exciting concept of active can-
cer immunotherapy [1].
Neoplastic initiation and progression are accompa-
nied by the accumulation of several genetic modifica-
tions in somatic cells. The transcriptional and mutational 
landscape of tumors indicates that there is a clear oppor-
tunity for the immune system to distinguish tumor cells 
from healthy tissue and trigger a specific attack against 
both conserved and mutated tumor-associated antigens 
(TAA) [2, 3]. Indeed, a high number of potential TAA 
has been identified for each individual type of cancer [2, 
4], making a more rational design and more sophisticated 
strategies for targeted anti-tumor vaccination a reality. In 
this evolving scenario, DNA vaccines represent an attrac-
tive and potentially effective tool for antigen-specific 
immunotherapy. Theoretically any mutated, abnormally 
expressed or over-expressed TAA could be exploited as 
a target to design a specific anti-cancer DNA vaccine, 
however, despite extensive effort by academia and indus-
try, only one cancer vaccine has been approved by the 
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U.S. Food and Drug Administration (FDA) so far [5]. The 
obstacles in successfully translating the virtually infinite 
number of potentially targetable TAA into effective anti-
cancer vaccines have highlighted that being a TAA does 
not necessarily mean to be a good target for immunother-
apy. Moreover, despite the existence of several successful 
immunotherapeutic strategies in mouse cancer models, 
their translation to human malignances fails because of 
unacceptable toxicity or a lack of efficacy [6, 7].
For these reasons, the clear need for more refined and 
predictive pre-clinical models becomes apparent. There-
fore, in 2003 the National Cancer Institute’s Center for 
Cancer Research introduced the Comparative Oncology 
Program in order to foster the study of naturally occur-
ring cancer in pet animals as models of human tumors 
[8, 9]. A European initiative with a similar purpose—the 
LUPA project—has also recently been launched [10]. The 
aim of comparative oncology is to integrate the naturally 
occurring cancers seen in veterinary patients into a more 
general study of cancer biology and therapy, to benefit 
both veterinary and human oncological patients [8, 9].
This review will highlight the role of chondroitin sulfate 
proteoglycan-4 (CSPG4) as one of the most attracting 
TAA identified so far for translational immunotherapy 
studies in both human and veterinary field.
The oncoantigen concept
Displaying a low level of expression in healthy tissues and 
a high level of expression in tumors, in addition to own a 
“driving” role in the promotion of cancer development—
pushing the progression of a neoplastic lesion from one 
stage to the next—are the features of “ideal” immuno-
therapeutic targets.
The term “oncoantigen” was coined to describe those 
TAA that display the above-mentioned characteristics 
[11, 12]. Their stable expression throughout the various 
tumor developmental stages and the key role in tumor 
growth and survival make oncoantigens normally not 
susceptible to immunoediting and even if oncoantigen-
loss variants might occur, they would have a crippled 
tumorigenic potential and undergo negative selection 
[13]. According to their localization, oncoantigens can 
be divided in three classes: (a) those expressed on the cell 
surface (Class I oncoantigens; receptors, adhesion mole-
cules, etc.); (b) those present in the tumor microenviron-
ment (Class II oncoantigens; growth factors, angiogenic 
factors, etc.); and (c) those that are intracellular proteins 
(Class III oncoantigens; non-receptor tyrosine kinases, 
transcription factors, cell cycle molecules). Being suscep-
tible to the attack of both T cells and antibodies, Class I 
oncoantigens are considered the ideal targets for effective 
anti-cancer immunotherapeutic strategies [12, 14, 15].
The expression level in neoplastic and/or cancer ini-
tiating cells (CIC), the cellular localization and the role 
in oncogenic pathways, together with the percentage of 
patients with tumors expressing a given TAA, are char-
acteristics also used by the National Cancer Institute of 
the U.S. to prioritize cancer antigens for the development 
of focused immunotherapeutic vaccines [16]. The CSPG4 
belongs to this list of promising TAA [16].
CSPG4 identification card: structure, function 
and distribution
CSPG4, high molecular weight-melanoma associated 
antigen (HMW-MAA) and melanoma chondroitin sulfate 
proteoglycan (MCSP) are different names to label a cell 
surface molecule with unique structural characteristics. 
CSPG4 was first characterized on human melanoma cells 
more than 30  years ago [17]; in the same period, other 
studies have identified the nerve/glial antigen 2 (NG2) 
that is the rat orthologue of CSPG4 [17, 18]. The com-
plete sequence of CSPG4 expressed by human melanoma 
cells was published in 1996 [19]: the gene, located on 
chromosome 15:24q2, is composed of 10 exons and the 
cDNA sequence length is of 8071 base pair (bp) encoding 
an open reading frame of 2322 amino acids (aa) [20, 21]. 
CSPG4 is a transmembrane protein that can be expressed 
on the cells either as a N-linked glycoprotein of ~250 kDa 
or as a  ~450  kDa  N-linked glycoprotein associated to a 
proteoglycan component [21]. The extracellular region of 
CSPG4 contains the sequences for the glycosylation with 
the chondroitin sulfate (CS) chains that can influence 
the distribution of the protein on the cell surface [22]. 
The large extracellular domain (1–2221 aa) is composed 
of three subdomains D1–D3 [17], encompassing bind-
ing sites for extracellular matrix (ECM) proteins, growth 
factors, integrins, matrix metalloproteinases and lectins. 
In particular, the D1 subdomain (1–640 aa) is an N-ter-
minal globular domain consisting of two laminin G-type 
regions (LGR) and abundant disulfide bonds critical to 
maintain the tertiary structure. In these regions there 
are sites for ligand binding, for integrins interactions and 
cell matrix or cell–cell connections. The D2 subdomain 
(641–1590 aa) is composed of a succession of 15 “CSPG 
repeat” motifs, some of which are binding sites for CS 
chains covalently attached, collagens V and VI, or FGF 
and PDGF growth factors [23, 24]. The D3 subdomain 
(1591–2221 aa) is a membrane proximal globular domain 
with binding sites for the galectin-3, β1 integrins, and 
other lectins (e.g., p-selectin) [25, 26]. This juxtamem-
brane region contains also some proteolytic sites for the 
CSPG4 cleavage. Actually, CSPG4 fragments have been 
widely described [27, 28]; tryptic products have been 
detected in sera from healthy donors and cancer patients 
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but their biological and clinical significance is still fairly 
unknown [26, 29, 30].
The extracellular portion of the CSPG4 is followed by 
a 25-aa transmembrane sequence (2222–2246 aa) joined 
to a 75-aa cytoplasmatic domain (2247–2322 aa) encom-
passing sites critical for CSPG4 function: (a) the PDZ 
binding domain on the carboxyl terminal portion that 
is the site for the attachment of scaffold proteins such as 
MUPP1, syntenin and GRIP1 [31]; (b) two multiple thre-
onine phosphoacceptor sites phosphorylated by PKCα 
and extracellular signal-regulated kinase (ERK) 1 and 2 
[32] and (c) a proline-rich region (PRR) that should pro-
mote other protein interactions [33]. A schematic depic-
tion of CSPG4 structure is represented in Fig. 1.
As a membrane-spanning molecule, CSPG4 plays 
an important role in the communication between the 
outside and the inside compartments of the cell. Nota-
bly, CSPG4 is devoid of a catalytic activity [34]; how-
ever, it can participate in signal transduction starring 
as co-receptor. Thanks to its extended extracellular 
arm, CSPG4 could “capture” and present growth fac-
tors to different tyrosine kinase receptors (RTK) or link 
the molecules of the ECM, including collagen type II, V, 
and VI, laminin, tenascin and fibronectin to integrins, 
potentiating and sustaining the activated pathways [17, 
35]. Along with enhancing growth factor activity and 
integrin-mediated pathways, CSPG4 could also serve as a 
direct cell surface receptor for ECM components [23, 36]. 
The intracellular domain serves as “central recruitment” 
for scaffolding proteins linking CSPG4 to intracellular 
signaling pathways and to the actin cytoskeleton [37]. All 
these features highlight the central key role of CSPG4 in 
orchestrating cell proliferation, adhesion, migration and 
survival.
CSPG4 is involved mainly in tissue development or 
homeostasis and retains a limited expression in adult 
healthy tissues [26]. Its expression was initially found in 
a limited number of normal cell types, including vascu-
lar pericytes, articular chondrocytes, and the microglia 
in the central nervous system. More recently, CSPG4 
mRNA expression has been detected in a broader range 
of tissues, including brain, gastrointestinal tract and 
endocrine organs, where it appears to be distinctive of 
precursor/progenitor cells of epithelial and mesodermal 
Fig. 1 Schematic drawing of CSPG4 protein. CS chondroitin sulfate, D1, D2 and D3 subdomains of the extracellular portion, TM transmembrane 
domain, ICD intracellular domain, LGR laminin G-type regions, PRR proline-rich region, PDZ PDZ binding domain. The most important molecules 
interacting with each subdomain of CSPG4 are indicated on the right. RTK receptor tyrosine kinase, ECM extracellular matrix, FGF fibroblast growth 
factors, PDGF platelet-derived growth factor, PKC protein kinase C, ERK extracellular signal-regulated kinases
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origin [38–41]. However, in normal tissues CSPG4 
mRNA expression levels do not correlate with the protein 
expression [41].
CSPG4 as a prototype oncoantigen in human 
tumors
Marked by a restricted distribution in normal tissues, 
CSPG4 is over-expressed in several haematological and 
solid neoplastic conditions besides melanomas, including 
oligodendrocytomas, gliomas, childhood acute lympho-
blastic leukemia and acute myeloid leukemia, renal cell 
carcinomas, chondrosarcomas, pancreatic and triple-
negative breast carcinomas. In neoplastic lesions CSPG4 
is highly expressed on both malignant cells and activated 
pericytes within the tumor microenvironment [42, 43]. 
The association between CSPG4 expression and patients’ 
poor prognosis suggests that CSPG4 is directly involved 
in the neoplastic progression [18, 24, 29, 41, 44–47]. The 
best-established implication regards the link between 
CSPG4 and melanoma progression that was first appreci-
ated as a result of its widespread expression in the major-
ity (85% or greater) of human melanomas [21, 48, 49].
As a consequence of its ability to coordinate several 
intracellular pathways regulating different cell func-
tions, CSPG4 becomes involved in tumorigenesis at 
multiple levels [41, 46]. Specifically, the over-expression 
of CSPG4 could sustain a high proliferative pheno-
type of tumor cells. By means of its ability to act as co-
receptor, binding to and presenting growth factors to 
their cognate RTK, CSPG4 could potentiate the activa-
tion of the mitogen-activated protein kinases (MAPK) 
pathway, resulting in the selective growth and survival 
advantage of CSPG4-positive tumor cells [50, 51]. Also 
in those melanomas in which the  BRAFV600E mutation 
determines a constitutive activation of the downstream 
MAPK pathway positively impacting on cell prolifera-
tion, the expression of CSPG4 is required to maximize 
the tumorigenic effect [52]. CSPG4 over-expression has 
also been involved in cancer cell progression through the 
regulation of intracellular pathways implicated in tumor 
cell adhesion and migration. Several studies have dem-
onstrated that integrin-mediated signaling can be super-
activated in the presence of CSPG4 over-expression, as 
compared to stimulation of integrins alone [52–54]. By 
binding ECM molecules and interacting with integrins, 
CSPG4 enhances integrin activation leading to the for-
mation of a complex with signal transduction molecules 
such as focal adhesion kinase (FAK), which is a key factor 
for initial cell spreading [55]. Through a FAK-independ-
ent mechanism, CSPG4 could increase the activation of 
ERK 1 and 2 and sustaining cancer cell migration also 
through this pathway [52]. Activated CSPG4 can as well 
recruit the tyrosine-phosphorylated  p130cas, an adaptor 
protein involved in the linkage of actin cytoskeleton to 
the extracellular matrix during cell migration, invasion 
and transformation [56, 57], contributing in this way to 
cytoskeletal reorganization and metastatic spread of 
CSPG4-positive tumor cells. In addition, several studies 
have demonstrated a role for CSPG4 in mediating multi-
drug resistance via stimulation of PI3K/Akt signaling [58, 
59]. Finally, it is thus not surprising that CSPG4 is over-
expressed on CIC [46, 60] and tumor-derived exosomes 
[61] that are emerging as major players in cancer devel-
opment and progression, contributing to recurrences, 
metastasis formation and chemoresistance [62–64].
CSPG4 oncoantigen: a new star on the stage 
of comparative oncology
In recent years, the study of naturally occurring tumors in 
pet animals as models of human cancer, i.e. the compara-
tive oncology, has been on the rise. Indeed, the difficulties 
in translating into the clinics several immunotherapeutic 
strategies found to be effective in rodents [6, 7] prompted 
the National Cancer Institute’s Center for Cancer Research 
[8] and, later on, a European Group [10] to launch the 
Comparative Oncology Program in order to find more 
informative pre-clinical models. In particular, the long his-
tory of dogs in biomedical research, their strong anatomi-
cal and physiological similarities to humans and the high 
number of pet dogs that are diagnosed with cancer and 
managed therapeutically, make these companion animals 
an attractive comparative model. Canine tumors mimic 
the progression of human malignancies better than any 
other pre-clinical model available so far since they grow 
over long periods of time following the natural evolution 
of human tumors, give rise to recurrences and metastases, 
and provide similar response to conventional therapies 
[9, 65, 66]. As a result, the study of spontaneous tumors 
developing in dogs as models for human malignancies is 
a priceless translational tool for accelerating the develop-
ment of novel immunotherapeutic strategies with a sub-
stantial impact on the management of both canine and 
human oncological patients. Several canine tumors are 
“under the microscope” of comparative oncology for their 
translational relevance; among them there are lymphosar-
comas, mammary carcinomas, melanomas and osteosar-
comas [9, 67–70].
At the light of the comparative oncology concepts and 
considering the biological role of the CSPG4 oncoantigen 
in human tumors and its high conservation in structural 
and functional properties through phylogenetic evolu-
tion, the identification of CSPG4 in canine tumors could 
represent an unprecedented opportunity to pre-clinically 
test anti-CSPG4 immunotherapies in the veterinary 
field, highly predictive of their clinical efficacy in the 
human oncology. With this in mind and considering the 
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well-known link between CSPG4 expression and mela-
noma progression in humans, other than the urgent need 
of effective strategies for the treatment of both human 
and canine melanomas [71–73], we were the first to eval-
uate CSPG4 expression in canine malignant melanomas 
[74]. About 60% of canine melanomas stained positive for 
CSPG4. The staining was mostly restricted to the tumor 
cell membrane with a different grade (or score) of expres-
sion in the different subtypes, being higher in epithelioid 
and in the more aggressive amelanotic phenotype. These 
findings labeled CSPG4 as a new potential marker for 
canine malignant melanoma diagnosis and as a promis-
ing candidate antigen for translational immunotherapy 
studies in dogs.
Moreover, we have evaluated the presence of CSPG4 
on different cell lines generated from three canine mela-
noma patients: one named OLGA, generated starting 
from the bioptic material obtained from a metastatic 
lymph node, and two lines named CMM9 and CMM10, 
derived from primary oral melanomas. CSPG4 expres-
sion on tumor cell membrane has been confirmed by 
flow cytometry analysis in all the canine melanoma cell 
lines analyzed (unpublished data, Fig. 2a), thus represent-
ing an interesting tool for the in  vitro study of CSPG4 
in a canine melanoma model. Besides, since in human 
tumors CSPG4 expression has been associated with the 
highly tumorigenic CIC subpopulation [46], we evalu-
ated the expression of CSPG4 also on CIC-enriched 
OLGA
CMM9
CMM10
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
Fo
ld
 C
ha
ng
e
O
L
G
A
O
L
G
A
 P
1
O
L
G
A
 P
2
a b
Fig. 2 CSPG4 expression in canine melanoma cells and derived-CIC. a CSPG4 expression levels in three canine melanoma cell lines: OLGA [121], 
CMM9 and CMM10 (kind gift from Dr. Sasaki Nobuo and Dr. Nakagawa Takayuki, Laboratory of Veterinary Surgery, University of Tokyo, Japan). Cells 
were maintained in Dulbecco’s modified Eagle’s medium (DMEM; Sigma-Aldrich) supplemented with 10% fetal bovine serum (FBS; Sigma-Aldrich), 
50 U/mL penicillin, and 50 μg/mL streptomycin (both from Invitrogen) in humidified incubator at 37 °C under 5%  CO2. 2 × 105 cells were incubated 
with a mix of CSPG4-specific mAb (225.28, VF4-TP108, VF20-TP108 and VF20-VT20; kindly provided by Prof. Soldano Ferrone, Massachusetts General 
Hospital, Boston, MA, USA) for 1 h at 4 °C. After washing with PBS, cells were incubated with a FITC-conjugated anti-mouse secondary antibodies for 
30 min at 4 °C. Flow cytometry was performed with a CyAn ADP (DakoCytomation) and the results were analyzed with Summit 4.2 (DakoCytoma-
tion) software. Black lines show CSPG4 expression, while dotted grey lines show the background of cells stained with FITC-conjugated anti-mouse 
secondary antibody alone. A representative staining of three independent experiments is reported. b For CIC-enrichment, epithelial melanoma 
cells were detached by using non-enzymatic and mechanical dissociation and plated in ultra-low-attachment flasks at 6 × 104 viable cells/mL in 
serum-free DMEM-F12 medium supplemented with 20 ng/mL basic fibroblast growth factor (FGF), 20 ng/mL epidermal growth factor (EGF), 5 µg/
mL insulin, and 0.4% bovine serum albumin (BSA). Non-adherent spherical clusters of cells (P1), were collected after 7 days and disaggregated using 
non-enzymatic and mechanical dissociation. P1-derived single-cell suspensions were seeded again at 6 × 104 viable cells/mL to generate non-
adherent spherical clusters of cells (P2). 1 μg of RNA extracted from OLGA, P1-OLGA and P2-OLGA was retrotranscribed using RETROscript™ rea-
gents (Ambion) and qPCR was carried out using gene-specific primers (Qiagen). Data were analyzed using SDS software 2.3 (Applied Biosystems). 
Relative CSPG4 gene expression was quantified using the threshold cycle (CT) value and normalized to housekeeping RNA18S. Relative expression 
of CSPG4 gene in the P1-OLGA and P2-OLGA compared with OLGA epithelial cells was calculated according to the method of Fold Change  (2−(Del-
taDelta CT)). Results representative of one out of three independent experiments is reported
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melanospheres obtained from canine cell lines. Prelimi-
nary results suggest a CSPG4 over-expression at mRNA 
level in the first two in vitro passages of OLGA-derived 
melanospheres (P1 and P2) as compared to the epithe-
lial counterpart (unpublished data, Fig.  2b), confirm-
ing CSPG4 as an attractive immunotherapeutic target 
potentially effective against recurrences and metastases 
in dogs.
Finally, as already shown for human tumors, it is 
likely that CSPG4 is expressed by other canine tumor 
histotypes besides malignant melanoma. Indeed, our 
immunohistochemical analysis of CSPG4 expression per-
formed on a cohort of 29 canine osteosarcoma patients, 
revealed 23 (79%) positive and 6 (21%) negative cases. 
Particularly, the positivity score assigned as previously 
described [74] among the 23 CSPG4-expressing osteo-
sarcomas was distributed as follow: 8 with a score of 8 
(34.8%), 5 with a score of 7 (21.7%), 5 with a score of 6 
(21.7%), 3 with a score of 5 (13.0%) and 2 with a score of 
4 (8.7%). These preliminary data suggest a widespread 
expression of CSPG4 in appendicular osteosarcomas 
(unpublished data, Fig.  3), the most common primary 
canine malignant bone tumor [75].
All together, these findings highlight the great value of 
CSPG4 as a translational immunotherapeutic target in 
veterinary clinical practice, not only for melanoma but 
also for other tumor types.
CSPG4 immune‑targeting
The development of anti-cancer therapies directed 
against CSPG4 represents an unprecedented opportunity 
to simultaneously target tumor cells, CIC and pericytes 
on tumor vasculature. Moreover, since CSPG4 orches-
trates multiple intracellular signaling pathways [35], its 
targeting could concurrently impair different oncogenic 
features of tumor cells. For these reasons several immu-
notherapeutic approaches against CSPG4 for the treat-
ment of melanoma and other CSPG4-expressing tumor 
histoypes have been tested both in pre-clinical and clini-
cal settings (Table 1).
One explored strategy in the immunotherapy field, con-
sisting in the stimulation of autologous tumor-specific 
lymphocytes ex vivo to improve cell mediated immunity 
before adoptively transferring them back to the patient, 
were first described almost four decades ago. Since then, 
several attempts to treat metastatic melanoma were car-
ried out exploiting the adoptive cell transfer (ACT) of 
autologous lymphocytes derived from the tumor or from 
the blood of patients [76–80]. Despite the induction of an 
objective cancer regression in a measurable proportion 
of treated patients, this strategy has several limitations, 
including the requirement of pre-existing antitumor-
reactive cells that should be expanded ex  vivo and the 
inadequate applicability in other cancer histotypes other 
than melanoma. The possibility of genetically engineering 
T cells with conventional T-cell receptors (TCRs) or chi-
meric antigen receptors (CARs) and consequently redi-
recting T lymphocytes to recognize and destroy specific 
TAA has opened up new opportunities for the utilization 
of ACT to treat different types of cancer patients [81]. 
Indeed, these T cell-based approaches have been already 
used in pre-clinical and clinical trials for the treatment of 
several types of malignancies, including melanoma, mye-
loma and haematologic malignancies [82–85]. On the 
wave of these novel approaches, CSPG4 has been con-
sidered a suitable target for CAR-T cells. Indeed, several 
CSPG4-specific CARs have been generated by utilizing 
monoclonal antibodies (mAbs) reactive against CSPG4 
Fig. 3 CSPG4 expression in canine osteosarcoma. Tissue samples 
from 29 canine osteosarcomas collected at the Diagnostic Labora-
tory of the Department of Animal Pathology of the University of Turin 
were examined. Data regarding breed, sex, age, tumor localization 
and clinical TNM staging were available for all dogs. The sample was 
fixed in 4% neutral buffered formalin, embedded in paraffin, and 
sectioned at 4 µm. Immunohistochemical analysis for CSPG4 was per-
formed as previously described [74]. Briefly, sections were exposed 
to high-temperature antigen unmasking by incubation at 98 °C with 
citric acid buffer, pH 6.0. Endogenous peroxidase activity was blocked 
with 3% hydrogen peroxide in methanol for 30 min at room tempera-
ture. Tissue sections were incubated for 12 h at room temperature 
with a polyclonal anti-CSPG4 antibody (diluted 1:40, Sigma Aldrich), 
then 30 min with biotinylated-secondary antibody (Vectastain Elite 
ABC) and revealed with the ImmPACT DAB kit for peroxidase. A total 
score considering the proportion of positively stained tumor cells and 
the average staining intensity was assigned as previously described 
[74]. Briefly, the score indicating the positivity of tumor cells was 
assigned as follow: 0 (none); 1 (<1/100 or <1%); 2 (1/100–1/10 or 
1–10%); 3 (1/10–1/3 or 10–30%); 4 (1/3–2/3 or 30–70%); and 5 (>2/3 
or >70%). The score representing the estimated average staining 
intensity of positive tumor cells encompass 0 if none, 1 weak, 2 inter-
mediate, 3 strong. The two scores were then added to each other to 
obtain a final score of CSPG4 expression ranging from 2 to 8. A repre-
sentative image from a canine appendicular osteosarcoma is shown. 
Neoplastic cells are characterized by diffuse and strong cytoplasmic 
and membrane immunolabeling for CSPG4 and the total expression 
score is 8, resulted by the sum of the percentage of positive cells (=5) 
and the staining intensity (=3). Magnification 20X
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and pre-clinically demonstrated anti-tumor activity 
against not only melanoma, but also against many other 
CSPG4-positive cancer histotypes, including breast car-
cinoma, head and neck squamous cell carcinoma and 
mesothelioma, as well as against CIC [85–88]. Moreover, 
Smidth and collaborators interestingly changed the pro-
spective of ACT therapy, demonstrating that the adoptive 
transfer of CARs directed against CD20 and CSPG4 mol-
ecules—co-expressed by less that 2% of melanoma cells—
is effective in the eradication of tumor lesions, while the 
targeting of any other minor subset is less effective [89]. 
In this way they revealed that melanoma lesions can be 
efficiently eradicated through the specific T cell-medi-
ated elimination of a definite melanoma cell population, 
highlighting the fundamental relevance of CSPG4 tar-
geting. Indeed, redirecting T cells to CSPG4 using CARs 
may represent a robust immunotherapeutic approach 
to target multiple solid tumors; however, till now, the 
clinical experience with engineered T cells is limited and 
some challenges have still to be overcome [90].
The importance of CSPG4 as a promising target for 
T cell-based immunotherapy has been also supported 
by Erfurt and colleagues, which demonstrated the pres-
ence of a  CD4+ T cells reactivity against specific peptides 
located in the extracellular domain of CSPG4 antigen in 
the peripheral blood of both healthy donors and mela-
noma patients, in the absence of clinical signs of autoim-
munity. Importantly, these peptide-specific  CD4+ T cells 
could strongly recognize CSPG4 expressing melanoma 
cells, suggesting that the identified peptides are naturally 
processed by tumor cells. These findings supported the 
idea that the activation and the expansion of CSPG4-
reactive  CD4+ T cells circulating in the blood could 
be considered for further development of anti-CSPG4 
immunotherapeutic strategies [91, 92].
However, since in several malignancies tumor cells 
have been reported to escape T-cell recognition [93, 94], 
more and more researchers have focused their atten-
tions on mAb-based therapies and several studies have 
investigated the potentiality of mAb-based anti-tumor 
strategies directed against CSPG4. This body of find-
ings solidly demonstrated, in different cancer cells and 
in various experimental settings, the efficacy of anti-
CSPG4 mAb in impairing cancer cell proliferation, 
migration and invasion. These effects are mediated by 
multiple mechanisms, including direct mAb activity, 
such as the induction of CSPG4 down-regulation and a 
reduced activation of CSPG4-dependent signaling path-
ways, and mAb dependent recruitment and activation 
of immune-effector mechanisms [45, 60, 95, 96]. More 
sophisticated mAb-based approaches, including chimeric 
anti-CSPG4 antibodies fused to super-antigens, bi- and 
tri-specific antibodies, or cytolytic fusion protein of 
CSPG4-specific single-chain antibody fragment geneti-
cally fused to microtubule-associated protein (MAP) tau, 
were also exploited [97–101], confirming the efficacy of 
the immune-targeting of CSPG4-positive cancer cells. 
Recent studies have also provided evidences of the posi-
tive impact of anti-CSPG4 mAb in improving the efficacy 
of anti-cancer drugs in glioblastoma and melanoma pre-
clinical models, indirectly associating the CSPG4 expres-
sion with multidrug resistance in these tumor histotypes 
[58, 102, 103].
An alternative approach to mAb administration is 
obviously active immunization, which has the poten-
tial to bring about effective and long-lasting anti-tumor 
responses without significant side effects and the risk of 
resistance development. First evidences of the effective-
ness of active immunization against CSPG4 in melanoma 
patients were achieved through vaccination with the 
anti-idiotypic antibody MK2-23, which bears the inter-
nal image of the mAb 763.74 against a defined CSPG4 
epitope. Interestingly, the induction of CSPG4-specific 
antibodies in immunized patients was associated with 
significantly longer survival and metastasis regression 
[104, 105]. However, this approach never ended up in 
clinics, due to both the difficulties in standardization of 
MK2-23 (it has to be conjugated to keyhole limpet hemo-
cyanin as a carrier) and to side effects associated with 
Bacille Calmette–Guerin administration required to 
induce an efficient immune response [106]. Alternative 
strategies evaluating in a pre-clinical setting the impact 
of the fusion of mAb MK2-23 with IL-2 demonstrated 
an enhanced immunogenicity of the novel construct and 
thus the possibility to bypass the requirement for conju-
gation to a carrier and administration with an adjuvant 
[106]. Moreover, anti-CSPG4 vaccination was again of 
interest when the mimotope technology emerged, indeed 
immunizations with CSPG4 mimotopes resulted in an 
inhibition of proliferation, migration and invasion of 
CSPG4-positive melanoma cells through the induction of 
a specific antibody response responsible for both immu-
nological and non-immunological antitumor functions 
[107–109].
Overall, these are encouraging data providing a strong 
rationale for the development of new strategies of active 
immunization against CSPG4.
DNA vaccination against CSPG4: a strategy 
for the treatment of canine malignant melanoma 
with translational implications
Amongst the various possible approaches for active 
immunization, DNA vaccination has some advantages 
over other strategies. Among them there are the high sta-
bility of DNA and the possibility to generate the vaccine in 
large amounts in a cheaper and faster manner than other 
Page 10 of 14Rolih et al. J Transl Med  (2017) 15:151 
vaccines [110]. DNA vaccines consist in circular DNA 
constructs (plasmids) that encode one or more TAA. 
Thanks to its bacterial derivation and to the presence of 
hypomethylated CpG dinucleotide-containing motifs, the 
plasmid is able per se to stimulate the innate immune sys-
tem by interacting with toll-like receptor (TLR)-9 [111] 
augmenting the antigen-specific immune response. The 
stimulation of a range of TLR9-expressing cells, including 
dendritic cells (DC) and B cells, can create an inflamma-
tory milieu for triggering the adaptive immune response 
[112]. Plasmids administration intradermally, subcutane-
ously or intramuscularly, results in transfection of resi-
dent cells, including DC and other antigen-presenting 
cells. This allows TAA expression and presentation on 
both MHC Class I and Class II molecules and stimulation 
of the cellular and the humoral arms of the immune sys-
tem against TAA-positive cancer cells (reviewed in [113]).
A large body of studies assessed the efficacy and the 
safety of the DNA vaccination technique for cancer treat-
ment and prevention in a variety of animal models and 
even in humans with plasmids encoding different TAA 
[114–120]. However, overall clinical benefit has been so 
far limited, despite the high efficacy of DNA vaccines in 
pre-clinical models [110]. A critical issue linked to the 
high failure of DNA vaccination approaches in the clinical 
trials could be related to the way of vaccine administration 
and design. The intramuscular administration of the DNA 
vaccine in association with electroporation is one of the 
most effective way of immunization identified so far [114]. 
Another major challenge in the development of success-
ful cancer DNA vaccines lies in the fact that most oncoan-
tigens, including CSPG4, are non-mutated and tolerated 
self-proteins. Therefore, there is the need of identifying 
a strategy to overcome the immune-tolerance normally 
existing in patients, in order to induce a proper long-term 
immune response towards self-antigens. The use of DNA 
plasmids coding for xenogeneic proteins is one interest-
ing strategy widely investigated in several pre-clinical 
and clinical studies that have demonstrated its efficacy 
[121–124]. Moreover, xenovaccination has recently been 
shown to improve survival in veterinary cancer patients, 
mainly in dogs affected by spontaneous disease [96, 121, 
125, 126]. Positive results obtained in veterinary trials 
led to the approval by the US FDA of the first xenoge-
neic DNA vaccine against tyrosinase, ONCEPT (Merial), 
for the treatment of oral malignant melanomas in dogs 
[5]. Although the therapeutic efficacy of ONCEPT has 
been recently questioned [127], its licensing has elicited 
enthusiasm for this immunization strategy as a potentially 
effective immunotherapeutic approach. Indeed, the use of 
a xenogeneic antigen could circumvent the immune toler-
ance because it preserves a high degree of similarity and, 
at the same time, is different enough from the targeted 
self-oncoantigen. Those differences between epitopes 
of the orthologue and the native protein are responsible 
for eliciting T and B cell responses against the xenoanti-
gen that may cross-react with the self-target. This makes 
the DNA vaccine highly immunogenic and consequently 
more likely effective.
The ability of xenogeneic DNA vaccines to break the 
immune tolerance and to induce an effective immune 
response against a self-oncoantigen has been exten-
sively demonstrated also by us [96, 114, 124, 128] and 
was applied to our anti-CSPG4 vaccine. Indeed, we have 
recently demonstrated the immunogenicity, safety and 
therapeutic efficacy of the electroporation of a xenoge-
neic DNA vaccine coding for the human CSPG4 (Hu-
CSPG4) protein in prospectively enrolled client-owned 
dogs with en bloc surgically resected stage II and III 
CSPG4-positive spontaneous oral malignant mela-
noma [96, 121]. The choice to use the human sequence 
of CSPG4 was due to the high conservation of CSPG4 
through evolution, with 82% of homology and 88% of 
similarity of the Hu-CSPG4 to the canine counterpart 
(Do-CSPG4). The results obtained in our studies demon-
strate the ability of the xenogeneic DNA vaccine against 
CSPG4 to induce a specific humoral response against 
the human protein coded by the plasmid and against 
the canine counterpart. This antibody response relates 
favorably with the significant prolongation of disease-free 
and overall survival time in vaccinated dogs with surgi-
cally resected malignant melanoma as compared to con-
trols treated with surgery alone [96, 121].
Conclusions
Our results indicate that CSPG4 xenogeneic DNA vacci-
nation associated to electroporation in dogs affected by 
MM is safe and able to overcome host unresponsiveness 
to the self-antigen, resulting in significantly increased 
overall and disease-free survival, thanks to the induction 
of anti-CSPG4 antibodies. These findings corroborate the 
clinical impact of CSPG4 immune-targeting for the man-
agement of canine melanoma patients. Moreover, the 
recognition of CSPG4 expression in other aggressive and 
incurable tumor histotypes may promote the spread of 
anti-CSPG4 vaccination strategy for the treatment of the 
wider population of CSPG4-positive tumor affected dogs. 
Finally, the recognized value of spontaneous tumors in 
dogs as a priceless model for predicting tumor behavior 
and response to immunotherapy in humans, highlights 
the translational potential of active CSPG4 immune-
targeting that might be revolutionary for the manage-
ment of both canine and human CSPG4-positive cancer 
patients.
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